Article citationsMore>>

Vlaar, A.P.J., de Bruin, S., Busch, M., Timmermans, S., van Zeggeren, I.E., Koning, R., et al. (2020) Anti-C5a Antibody IFX-1 (Vilobelimab) Treatment versus Best Supportive Care for Patients with Severe COVID-19 (PANAMO): An Exploratory, Open-Label, Phase 2 Randomized Controlled Trial. The Lancet Rheumatology, 2, e764-e773.
https://doi.org/10.1016/S2665-9913(20)30341-6

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top